Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CMS And FDA Stand Together Behind FDA Oversight Of LDTs At House Hearing

This article was originally published in The Gray Sheet

Executive Summary

CMS Deputy Administrator for Innovation and Quality Patrick Conway and FDA Device Center Director Jeffrey Shuren told a House subcommittee that legislators’ efforts to replace FDA’s proposed laboratory-developed test framework would lead to duplicative, time-consuming, expensive regulation, and could only result in ineffective and delayed diagnostics that might harm patients.


Related Content

Sen. Alexander Wants To ‘Start From Scratch’ In Regulating Lab-Developed Tests
Don't Finalize LDT Guidance, House Appropriators Tell FDA
Lab Group Urges FDA To Wait For Congress On LDT Issue
Shuren In The Lion’s Den: Device Center Chief Defends LDT Plan At Clinical Lab Meeting, Fields Wide Array Of Questions
CDRH Guidance Priorities Include Lab-Developed Tests, Adverse Event Reporting, Third-Party 510(k) Review
Capitol Hill Briefs
On Eve Of House Hearing, FDA Makes Its Case For LDT Framework
House Diagnostics Reg Reform Draft Proposes Pathways For Relaxed Scrutiny
FDA Plan To Regulate LDTs Includes Long Phase-In, Unmet-Need Exceptions
LabCorp Pulls OvaSure, But Charges FDA With Overreaching